TRAF6 and lobular neoplasia: (E)-2-(2-Chlorostyryl)-3,5,6-trimethylpyrazine (CSTMP) is a useful agent for the treatment of LN due to the inhibition of the TLR4/MyD88/TAK1/TRAF6/IRAK1 pathway [100].